NASDAQ:BPTS

Biophytis Competitors

$10.70

+0.06 (+0.56 %)

(As of 06/23/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.70

▼

$11.20

50-Day Range

$10.20

▼

$15.00

52-Week Range

$10.20

▼

$18.50

Volume2,608 shs

Average Volume12,296 shs

Market Capitalization$121.77 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Biophytis (NASDAQ:BPTS) Vs. VKTX, NBRV, TXMD, MTEM, AKUS, and SIGA

Should you be buying BPTS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Biophytis, including Viking Therapeutics (VKTX), Nabriva Therapeutics (NBRV), TherapeuticsMD (TXMD), Molecular Templates (MTEM), Akouos (AKUS), and SIGA Technologies (SIGA).

Biophytis vs. Viking Therapeutics Stock

Viking Therapeutics (NASDAQ:VKTX) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares Viking Therapeutics and Biophytis' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-17.58%	-16.83%
Biophytis	N/A	N/A	N/A

Institutional and Insider Ownership

52.6% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 2.6% of Biophytis shares are owned by institutional investors. 3.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Viking Therapeutics and Biophytis' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	$-39,490,000.00	($0.54)	-11.31
Biophytis	N/A	N/A	$-19,480,000.00	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for Viking Therapeutics and Biophytis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	0	0	9	0	3.00
Biophytis	0	0	0	0	N/A

Viking Therapeutics presently has a consensus target price of $15.3750, suggesting a potential upside of 151.64%. Given Viking Therapeutics' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Biophytis.

Summary

Viking Therapeutics beats Biophytis on 4 of the 7 factors compared between the two stocks.

Biophytis vs. Nabriva Therapeutics Stock

Nabriva Therapeutics (NASDAQ:NBRV) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nabriva Therapeutics and Biophytis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0	1	1	0	2.50
Biophytis	0	0	0	0	N/A

Nabriva Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 347.76%. Given Nabriva Therapeutics' higher possible upside, equities research analysts plainly believe Nabriva Therapeutics is more favorable than Biophytis.

Valuation & Earnings

This table compares Nabriva Therapeutics and Biophytis' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$5.03 million	94.36	$-69,480,000.00	($5.20)	-0.26
Biophytis	N/A	N/A	$-19,480,000.00	N/A	N/A

Biophytis has lower revenue, but higher earnings than Nabriva Therapeutics.

Institutional & Insider Ownership

0.9% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 2.6% of Biophytis shares are held by institutional investors. 2.8% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Nabriva Therapeutics and Biophytis' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-506.93%	-81.28%	-52.84%
Biophytis	N/A	N/A	N/A

Summary

Biophytis beats Nabriva Therapeutics on 5 of the 9 factors compared between the two stocks.

Biophytis vs. TherapeuticsMD Stock

TherapeuticsMD (NASDAQ:TXMD) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

44.3% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 2.6% of Biophytis shares are owned by institutional investors. 8.8% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares TherapeuticsMD and Biophytis' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-229.09%	N/A	-77.22%
Biophytis	N/A	N/A	N/A

Earnings & Valuation

This table compares TherapeuticsMD and Biophytis' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$64.87 million	7.27	$-183,520,000.00	($0.68)	-1.76
Biophytis	N/A	N/A	$-19,480,000.00	N/A	N/A

Biophytis has lower revenue, but higher earnings than TherapeuticsMD.

Analyst Recommendations

This is a breakdown of recent recommendations for TherapeuticsMD and Biophytis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	3	0	2.50
Biophytis	0	0	0	0	N/A

TherapeuticsMD currently has a consensus price target of $5.0667, suggesting a potential upside of 322.22%. Given TherapeuticsMD's higher possible upside, equities research analysts clearly believe TherapeuticsMD is more favorable than Biophytis.

Summary

TherapeuticsMD beats Biophytis on 5 of the 8 factors compared between the two stocks.

Biophytis vs. Molecular Templates Stock

Biophytis (NASDAQ:BPTS) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Biophytis and Molecular Templates, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0	0	0	0	N/A
Molecular Templates	0	1	3	0	2.75

Molecular Templates has a consensus target price of $14.50, indicating a potential upside of 72.82%. Given Molecular Templates' higher possible upside, analysts plainly believe Molecular Templates is more favorable than Biophytis.

Profitability

This table compares Biophytis and Molecular Templates' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Molecular Templates	-611.90%	-138.03%	-60.44%

Earnings & Valuation

This table compares Biophytis and Molecular Templates' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	$-19,480,000.00	N/A	N/A
Molecular Templates	$18.84 million	24.98	$-104,920,000.00	($2.13)	-3.94

Biophytis has higher earnings, but lower revenue than Molecular Templates.

Insider and Institutional Ownership

2.6% of Biophytis shares are owned by institutional investors. Comparatively, 63.0% of Molecular Templates shares are owned by institutional investors. 27.5% of Molecular Templates shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Molecular Templates beats Biophytis on 5 of the 9 factors compared between the two stocks.

Biophytis vs. Akouos Stock

Biophytis (NASDAQ:BPTS) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biophytis and Akouos, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0	0	0	0	N/A
Akouos	0	1	4	0	2.80

Akouos has a consensus target price of $30.00, indicating a potential upside of 120.59%. Given Akouos' higher possible upside, analysts plainly believe Akouos is more favorable than Biophytis.

Earnings & Valuation

This table compares Biophytis and Akouos' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	$-19,480,000.00	N/A	N/A
Akouos	N/A	N/A	$-48,600,000.00	($2.77)	-4.91

Profitability

This table compares Biophytis and Akouos' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Akouos	N/A	-17.21%	-16.05%

Insider & Institutional Ownership

2.6% of Biophytis shares are owned by institutional investors. Comparatively, 96.1% of Akouos shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biophytis vs. SIGA Technologies Stock

Biophytis (NASDAQ:BPTS) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Biophytis and SIGA Technologies' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	$-19,480,000.00	N/A	N/A
SIGA Technologies	$124.96 million	3.71	$56.34 million	$0.77	7.92

SIGA Technologies has higher revenue and earnings than Biophytis.

Profitability

This table compares Biophytis and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
SIGA Technologies	50.59%	56.02%	46.77%

Analyst Recommendations

This is a summary of current recommendations for Biophytis and SIGA Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0	0	0	0	N/A
SIGA Technologies	0	0	0	0	N/A

Institutional and Insider Ownership

2.6% of Biophytis shares are held by institutional investors. Comparatively, 26.8% of SIGA Technologies shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

SIGA Technologies beats Biophytis on 7 of the 7 factors compared between the two stocks.